Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies
By Tasmina Hydery
Xcenda and FormularyDecisions joined AMCP for a live webinar on Tuesday, June 21, 2022 titled, “Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies.”
Cell and gene therapies promise to potentially transform the management of devastating and life-threatening chronic diseases for many patients. However, life sciences companies developing these innovative therapies continue to face reimbursement and patient access challenges.
From these presentation slides, you’ll learn more on:
- A summary of approved and investigational cell and gene therapies in late-stage development
- Common reimbursement and access challenges for cell and gene therapies, including payment methodologies, correct coding, and billing
- Review an inpatient case study for Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel)